NEWLY DISCOVERED ANTIBIOTIC KILLS PATHOGENS WITHOUT RESISTANCE

For years, pathogens resis­tance to antibi­otics has put them one step ahead of researchers, which is causing a public health crisis. But in new research, led by the researchers at the present study discloses that  a newly dis­cov­ered antibi­otic has been identified  that elim­i­nates pathogens without encoun­tering any detectable resistance -- a finding that chal­lenges long-​​held sci­en­tific beliefs and holds great promise for treating chronic infec­tions like tuber­cu­losis caused by Mycobacterium tuberculosis, diseseases caused by Streptococcus sp.

The work is mainly carried out by the North­eastern researchers led by Lewis along with the northeastern biology professor Slava Epstein and in association with NovoBiotic Pharmaceuticals in Cambridge and Selcia ltd. UK. They played an important role in   developing a novel method for growing uncul­tured bac­teria led to the dis­covery of the antibi­otic, called teixobactin, and also ana­lyzing and testing the com­pound for resis­tance from pathogens. It is supposed to be the first discovery of an antibi­otic to which resis­tance by muta­tions of pathogens have not been identified.

The research team says teixobactin's dis­covery presents a promising new oppor­tu­nity to treat chronic infec­tions caused by staphy­lo­coccus aureus, that are highly resis­tant to antibi­otics, as well as tuber­cu­losis, which involves a com­bi­na­tion of ther­a­pies with neg­a­tive side effects.

The screening of soil microor­gan­isms has pro­duced most antibi­otics, but only 1% of them will grow in the lab, and this lim­ited resource was over­mined. The reserachers  spent years seeking to address this problem by tap­ping into a new source of antibi­otics beyond those cre­ated by syn­thetic means: uncul­tured bac­teria, which make up 99% of all species in external envi­ron­ments. The scientists have devel­oped a novel method for growing uncul­tured bac­teria in their nat­ural envi­ron­ment. The approach of developing the same  involves the iChip, a minia­ture device Epstein's team cre­ated that can iso­late and help grow single cells in their nat­ural envi­ron­ment and thereby pro­vides researchers with much improved access to uncul­tured bac­teria.

The antibi­otic was dis­cov­ered during a rou­tine screening for antimi­cro­bial mate­rial using the above method. Lewis then tested the com­pound for resis­tance devel­op­ment and did not find mutant       Mycobac­terium tuber­cu­losis resis­tant to teixobactin, which was found to block sev­eral dif­ferent tar­gets in the cell wall syn­thesis pathway.

In 2013, Lewis revealed ground­breaking research in a sep­a­rate paper pub­lished byNature that pre­sented a novel approach to treat and elim­i­nate tuberculosis and other non resistant disease.

---

Study show that reprogramming stem cells can prevent cancer following full body radiation

The body has evolved ways to get rid of faulty stem cells. A study conducted in the University of Colorado Cancer Center shows that one of these ways is a "program" that makes stem cells damaged by radiation differentiate into other cells that can no longer survive forever. Radiation makes a stem cell lose its "stemness."

The study also shows that this same safeguard of "programmed mediocrity" that weeds out stem cells damaged by radiation allows blood cancers to grow in cases when the full body is irradiated. And by reprogramming this safeguard, we may be able to prevent cancer in the aftermath of full body radiation.

Our body is not evolve to deal with leaking nuclear reactors and CT scans. It is evolved to deal with only a few cells at a time receiving dangerous doses of radiation or other insults to their DNA .

The team that carried out the research in the same explored the effects of full body radiation on the blood stem cells of mice. In this case, radiation increased the probability that cells in the hematopoietic stem cell system would differentiate. Only, while most followed this instruction, a few did not. Stem cells with a very specific mutation were able to disobey the instruction to differentiate and retain their "stemness". Genetic inhibition of the gene C/EBPA allowed a few stem cells to keep the ability to act as stem cells. With competition from other, healthy stem cells removed, the stem cells with reduced C/EBPA were able to dominate the blood cell production system. In this way, the blood system transitioned from C/EBPA+ cells to primarily C/EBPA- cells.

Mutations and other genetic alterations resulting in inhibition of the C/EBPA gene are associated with acute myeloid leukemia in humans. Thus, it's not mutations caused by radiation but a blood system reengineered by faulty stem cells that creates cancer risk in people who have experienced radiation.

Usually in the healthy blood system, healthy stem cells out-compete stem cells that happen to have the C/EBPA mutation. But when radiation reduces the heath and robustness  of the stem cell population, the mutated cells that have been there all along are suddenly given the opportunity to take over.

These studies not only tell us why radiation makes hematopoietic stem cells (HSCs) differentiate but it also states that they also show activating a stem cell maintenance pathway. Even months after irradiation, artificially activating the NOTCH signaling pathway of irradiated HSCs lets them act "stemmy" again - restarting the blood cell assembly line in these HSCs that would have otherwise differentiated in response to radiation.

When researchers tried to activate NOTCH in previously irradiated HSCs, it kept the population of dangerous, C/EBPA cells at bay. Competition from non-C/EBPA-mutant stem cells, with their fitness restored by NOTCH activation, meant that there was no evolutionary space for C/EBPA-mutant stem cells.

The scientist who carried out the research said "If I were working in a situation in which I was likely to experience full-body radiation, I would freeze a bunch of my HSCs, explaining that an infusion of healthy HSCs after radiation exposure would likely allow the healthy blood system to out-compete the radiation-exposed HSC with their "programmed mediocrity" (increased differentiation) and even HSC with cancer-causing mutations.

But there's also hope that in the future, we could offer drugs that would restore the fitness of stem cells left over after radiation.